N/a
-$10m ATM on Monday March 2 2020
-Coronavirus sympathy
-Emergent to manufacture Vaxart's experimental COVID-19 vaccine
-Jun 25 2020: Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP
-Jun 26 2020: COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed
-Jul 13 2020: Closes $90m ATM
-Aug 10 2020: Filed IND for COVID-19 vaccine
-Sep 14 2020: announces FDA clearance of IND application for oral COVID-19 vaccine
-SPY pattern: Consolidation
-Intraday pattern: Bull Flag
-Other notes: Large float and hard to read direction
Strategy: First test long of 6.9 level
Confluence: N/a
Strike Zone: 6.9
Sizing (lots + emergency): 1000
Risk (stop / Rs): 6.87
Kind of pissed at myself for stopping out, I was trying to keep my risk tight and was risking the low of the current down leg at 6.88 but it ended up hurting me in the end.
A stop shouldn't be triggered by small movements in price, if stopping it should be clear that opposite side is in control (market orders swiping several cents)...
Lessons Learned:
Execution detail:
Date/time | Symbol | Side | Price | Position |
---|---|---|---|---|
2020-09-14 11:20:37 | VXRT | buy | $6.930 | long |
2020-09-14 11:20:37 | VXRT | buy | $6.930 | long |
2020-09-14 11:20:37 | VXRT | buy | $6.930 | long |
2020-09-14 11:22:36 | VXRT | buy | $6.905 | long |
2020-09-14 11:22:36 | VXRT | buy | $6.910 | long |
2020-09-14 11:22:36 | VXRT | buy | $6.910 | long |
2020-09-14 11:22:36 | VXRT | buy | $6.910 | long |
2020-09-14 11:22:36 | VXRT | buy | $6.910 | long |
2020-09-14 11:25:37 | VXRT | sell | $6.910 | long |
2020-09-14 11:25:37 | VXRT | sell | $6.910 | long |
2020-09-14 11:25:37 | VXRT | sell | $6.910 | long |
2020-09-14 11:25:37 | VXRT | sell | $6.910 | long |
2020-09-14 11:26:52 | VXRT | sell | $6.860 | long |
2020-09-14 11:26:52 | VXRT | sell | $6.860 | 0 |
You need to log into your Tradervue account to leave a comment. If you don't have one,
it takes
just a few seconds to sign up, and it's free!
Hey Beno I looked your trades... it seems you have much room to improve... especially your risk/profit ratio...